Scholarlink

Background <p>Gemcitabine-based neoadjuvant therapy is frequently employed to enable curative resection of pancreatic ductal adenocarcinoma. Gemcitabine plus nab-paclitaxel (GnP) is often given to patients who relapse post-resection, resulting in multiple courses of gemcitabine-containing treatment regimens. However, the effect of prior gemcitabine-based neoadjuvant therapy on the efficacy of GnP therapy remains unclear. This study aimed to determine whether prior gemcitabine-based neoadjuvant therapy affects the therapeutic outcomes of GnP in patients with recurrent pancreatic ductal adenocarcinoma following curative resection.</p> Methods <p>We retrospectively analyzed 51 patients with resectable and borderline resectable pancreatic ductal adenocarcinoma who received gemcitabine-based neoadjuvant chemoradiotherapy, underwent curative-intent surgery, and were treated with GnP post-recurrence. Patients were divided into high-regression (≥ 30% reduction in tumor diameter; 32 patients) and low-regression (&lt; 30%; 19 patients) groups based on the tumor reduction rate during neoadjuvant therapy.</p> Results <p>Multivariate analysis identified tumor regression and the time from surgery to recurrence as independent prognostic factors for progression-free survival of GnP therapy following recurrence. Median progression-free survival was significantly longer in the high-regression group (11.8 vs. 5.8&#xa0;months, p = 0.010). The objective response rate to GnP was significantly higher in the high-regression than low-regression groups (43.8% vs. 10.5%; p = 0.015).</p> Conclusions <p>Patients with greater tumor regression during gemcitabine-based neoadjuvant therapy had better progression-free survival and treatment response to GnP therapy following recurrence. These findings suggest that treatment response to neoadjuvant therapy correlates with post-recurrence outcomes and contributes to the advancement of treatment strategies for recurrent pancreatic ductal adenocarcinoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarcinoma

  • 期刊论文

  • 发表日期：

    2026年7月4日

查看全文
  • Takumi Kinomoto,
  • Kenji Ikezawa,
  • Kunihito Gotoh,
  • Yugo Kai,
  • Ryoji Takada,
  • Takanori Masumoto,
  • Masaki Kawabata,
  • Hiroki Kishimoto,
  • Kana Ito,
  • Makiko Urabe,
  • Kaori Mukai,
  • Tasuku Nakabori,
  • Minoru Shigekawa,
  • Hirofumi Akita,
  • Hidenori Takahashi,
  • Shogo Kobayashi,
  • Kazuyoshi Ohkawa

摘要

Background

Gemcitabine-based neoadjuvant therapy is frequently employed to enable curative resection of pancreatic ductal adenocarcinoma. Gemcitabine plus nab-paclitaxel (GnP) is often given to patients who relapse post-resection, resulting in multiple courses of gemcitabine-containing treatment regimens. However, the effect of prior gemcitabine-based neoadjuvant therapy on the efficacy of GnP therapy remains unclear. This study aimed to determine whether prior gemcitabine-based neoadjuvant therapy affects the therapeutic outcomes of GnP in patients with recurrent pancreatic ductal adenocarcinoma following curative resection.

Methods

We retrospectively analyzed 51 patients with resectable and borderline resectable pancreatic ductal adenocarcinoma who received gemcitabine-based neoadjuvant chemoradiotherapy, underwent curative-intent surgery, and were treated with GnP post-recurrence. Patients were divided into high-regression (≥ 30% reduction in tumor diameter; 32 patients) and low-regression (< 30%; 19 patients) groups based on the tumor reduction rate during neoadjuvant therapy.

Results

Multivariate analysis identified tumor regression and the time from surgery to recurrence as independent prognostic factors for progression-free survival of GnP therapy following recurrence. Median progression-free survival was significantly longer in the high-regression group (11.8 vs. 5.8 months, p = 0.010). The objective response rate to GnP was significantly higher in the high-regression than low-regression groups (43.8% vs. 10.5%; p = 0.015).

Conclusions

Patients with greater tumor regression during gemcitabine-based neoadjuvant therapy had better progression-free survival and treatment response to GnP therapy following recurrence. These findings suggest that treatment response to neoadjuvant therapy correlates with post-recurrence outcomes and contributes to the advancement of treatment strategies for recurrent pancreatic ductal adenocarcinoma.